Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE-DEEM: Dabigatran in Acute Coronary Syndromes
NCT00621855Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2008
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 2, randomised, double-blind trial of dabigatran in acute coronary syndrome (ACS) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Composite of Major and Clinically Relevant Minor Bleeding Events at 6 months. Started Mar 2008; status: completed.
02
Drugs
dabigatran
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00621855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621855.